Literature DB >> 2392743

[Blood and urine determinations of tissue polypeptide antigen in patients with bladder carcinoma].

A Tizzani1, G Casetta, A Cavallini, P Piana, P Piantino.   

Abstract

The Tissue Polypeptide Antigen (TPA) is an oncofetal antigen widely used in the diagnosis and follow-up of several urothelial cancers. Its urinary and serum detection is performed by means of RIA technique. We determined urinary and serum TPA in 30 patients with bladder cancer who underwent a transurethral resection. Ten out of 30 patients were correctly diagnosed by serum TPA, 22 by urinary TPA. The ANOVA test showed a statistically significant correlation between grade and urinary TPA between stage and serum TPA. Urinary TPA showed a good sensibility in low grade and moreover in Ta stage carcinoma. Serum TPA increased its performance with higher grade carcinoma and in presence of a muscle infiltration, but it never reached a sufficient sensibility to be considered a bladder cancer marker. In conclusion the simultaneous determination of urinary and serum TPA does not give more information than the urinary determination alone.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2392743

Source DB:  PubMed          Journal:  Minerva Urol Nefrol        ISSN: 0393-2249            Impact factor:   3.720


  3 in total

1.  Value of carcinoembryonic antigen and cytokeratins for the detection of recurrent disease following curative resection of colorectal cancer.

Authors:  Luis C Fernandes; Su B Kim; Sarhan S Saad; Delcio Matos
Journal:  World J Gastroenterol       Date:  2006-06-28       Impact factor: 5.742

2.  Cytokeratins and carcinoembryonic antigen in diagnosis, staging and prognosis of colorectal adenocarcinoma.

Authors:  Luís C Fernandes; Su B Kim; Delcio Matos
Journal:  World J Gastroenterol       Date:  2005-02-07       Impact factor: 5.742

3.  Tissue polypeptide antigen and carcinoembryonic antigen lack diagnostic accuracy in urothelial carcinoma.

Authors:  V Stefanović; M Mitić-Zlatković; I Ignjatović; M Vlajković; Z Sćepović
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.